Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced participation in a fireside chat by CEO Tom Hallam, Ph.D., at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at 11:30 AM ET in New York, NY. The chat will be followed by one-on-one meetings with investors. A live video webcast will also be available for 90 days on the Palisade Bio website. The company focuses on therapeutics for gastrointestinal complications, with its lead program, LB1148, in Phase 3 studies.
- None.
- None.
Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET
CARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY.
In addition to the fireside chat, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website here.
A live video webcast of the fireside chat will be available in the Events section of the Investors & News page of Palisade Bio website (palisadebio.com) and will be accessible for 90 days.
About Palisade Bio
Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.
The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a pivotal Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.
The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company’s ability to achieve additional financing to fund clinical development and the company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com
Source: Palisade Bio
FAQ
What is the date of Palisade Bio's fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference?
Who will represent Palisade Bio during the fireside chat?
Where can I watch the Palisade Bio fireside chat?
What is the focus of Palisade Bio's lead program, LB1148?
How long will the webcast of the Palisade Bio fireside chat be available?
